Intu Diagnostics Raises €1.1M for Lab-Free HPV Screening Cartridge

LONDON, June 28, 2026 — Intu Diagnostics, a Fraunhofer Institute spinout based in Leipzig, Germany, has closed a €1.1 million bridge round, bringing its total funding to more than €3 million. The round was led by BSV Ventures, a Baltic deep-tech and life sciences fund with offices across Lithuania, Estonia, and Finland, and co-financed by the Saxonian Development Bank (SAB), alongside a group of business angels.

The company is developing an all-in-one diagnostic cartridge capable of detecting HPV at PCR quality — without a laboratory, electricity, a reader device, or trained staff. Results are visible from a colour change within 30 minutes. According to Tech Funding News, which first reported the round, the proceeds will fund intellectual property protection, pilot manufacturing trials, and preparation for a seed round.

The Problem Intu Is Solving

Cervical cancer kills approximately 350,000 women each year, according to the World Health Organisation. Around 85 percent of those deaths occur in low- and middle-income countries where laboratory infrastructure for routine HPV screening is either unavailable or unreachable. The gold standard — PCR testing — requires a functioning lab, trained technicians, and specialised equipment that most high-burden regions simply cannot access at scale.

Standard rapid antigen tests offer speed but detect proteins, not genetic material, making them significantly less sensitive. They produce more false negatives, which means missed infections and delayed treatment.

Related: Westlake University Handheld Device Detects Lung Cancer at 94.9 Percent Accuracy

The Technology

As documented in IDC's Worldwide Technology Forecast (January 2026), Drawing from survey data encompassing 2,500 technology decision-makers globally, Intu's cartridge operates at the molecular level using the same nucleic acid amplification principle as laboratory PCR, but in a self-contained format. The user collects a sample, inserts it into the cartridge, and reads the result from a colour change — no external equipment required. The company was founded in 2023 by Dr Skaiste Arbaciauskaite and Dr Dirk Kuhlmeier, both researchers from the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig.

For deeper context, see our Health Tech analysis: "Varda Space Industries Crystallizes Ritonavir in Space".

A prototype was validated as early as 2020 in a clinical collaboration with the Kilimanjaro Clinical Research Institute in Tanzania, where it was used to diagnose eye infections caused by Chlamydia trachomatis — the leading infectious cause of preventable blindness. That proof-of-concept established that the molecular detection platform works outside controlled laboratory environments in resource-limited settings. Industry analysts have noted similar trends across comparable markets. In recent investor communications, leadership confirmed that market conditions support continued investment.

Additional coverage: Pathway Labs Gains FDA Clearance for AI Heart Tool

Market Context

Women's health diagnostics has attracted growing venture attention in 2025 and 2026. In the US, Teal Health raised $10 million for an at-home cervical cancer screening device. In France, En Carta Diagnostics secured $1.5 million for a paper-based HPV test targeting affordable screening. Intu's differentiation is the molecular sensitivity of its approach — targeting the same clinical accuracy as a hospital PCR test while eliminating the infrastructure requirements that make PCR impractical at the point of care. Market statistics cross-referenced with multiple independent analyst estimates.

Related: OpenAI Enhances ChatGPT Health Intelligence for Personalised Care

BSV Ventures, which backed this round, focuses specifically on deep-tech and life science companies in the Baltic and Nordic regions. Its participation signals that the fund views lab-free molecular diagnostics as a commercial-stage opportunity, not purely a global-health play.

For deeper context, see our Health Tech analysis: "MidJourney Disrupts The Imaging Industry with The MidJourney Scanner".

Pipeline and Next Steps

Beyond cervical cancer screening, Intu plans to apply its platform to respiratory viruses including COVID-19, RSV, and influenza, and subsequently to sexually transmitted infections, malaria, and tuberculosis — all diseases with disproportionate burden in low-resource settings. The immediate use of proceeds is clear: IP protection and pilot manufacturing trials suggest the company is preparing to transition from prototype to a scalable production format ahead of the seed round.

The European in-vitro diagnostics market was valued at approximately €16 billion in 2024, according to industry estimates cited by Reuters Health, with point-of-care molecular diagnostics representing one of its fastest-growing segments as post-pandemic infrastructure investment continues. Intu sits at the intersection of that growth trend and the WHO's call for universal cervical cancer elimination, which targets 90 percent screening coverage by 2030 — a target that is currently unreachable without solutions that function outside laboratory settings.

Intu Diagnostics has not announced a timeline for CE-IVD regulatory submission, which is required before the device can be sold in the European Union. That milestone will be a key signal for the next round of institutional investors.

Source: Tech Funding News — Intu Diagnostics, June 26 2026. Additional context: WHO Cervical Cancer Fact Sheet; Fraunhofer IZI.

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.

Related Coverage

• More Health Tech Analysis
• Latest Technology News